Healio
SearchLoading
Healio
SearchLoading
More about

Cobimetinib

News
November 29, 2022
1 min read
Save

Immunotherapy added to BRAF/MEK inhibitor improves OS for anaplastic thyroid cancer

The triplet combination of vemurafenib/cobimetinib/atezolizumab showed improvement in overall survival in patients with BRAF-mutated anaplastic thyroid cancer, according to research presented at American Thyroid Association Annual Meeting.

News
November 03, 2022
1 min read
Save

FDA approves cobimetinib for histiocytic neoplasms

The FDA granted accelerated approval to cobimetinib for treatment of certain patients of histiocytic neoplasms.

News
July 30, 2020
1 min read
Save

FDA approves Tecentriq plus Cotellic and Zelboraf for advanced melanoma

The FDA today approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600-positive advanced melanoma, according to a manufacturer-issued press release.